1 Many studies indicate an involvement of substance P in the transmission of nociceptive stimuli, without, however, presenting any conclusive evidence as to its exact site and mode of action. The present experiments tested the involvement of substance P in the mediation of chemical nociception using the non-peptidic specific tachykinin NK,-receptor antagonist, RP 67580 (2-[1-imino-2-(2-methoxyphenylethyl]-7,7diphenyl-4-perhydroisoindolone (3aR, 7aR) 
Introduction
Both anatomical and functional studies indicate an involvement of substance P in the spinal transmission of noxious stimuli (see Otsuka & Yoshioka, 1993) . Up to now, however, no conclusive evidence exists as to whether substance P acts as a transmitter per se at the first spinal synapse or whether it only facilitates the action of glutamate (Dougherty & Willis, 1991; Mjellem-Joly et al., 1992; Rusin et al., 1992; . Part of the evidence stems from the fact that non-peptidic antagonists of the NKI-receptor, like CP-96,345 or RP 67580, display antinociceptive action, mainly in models of chemonociception (Garret et al., 1991; 1992; Yamamoto & Yaksh, 1991; Berge & StAhlberg, 1993; Chapman & Dickenson, 1993; Yashpal et al., 1993) . Regarding models of thermal nociception, however, reports on the effectiveness of these antagonists are conflicting (Lecci et al., 1991; Radhakrishnan & Henry, 1991; Berge & Stahlberg, 1993; Szolcsanyi et al., 1993) . Contrary to the early antagonist substance P analogues, the new compounds are devoid of neurotoxic effects and are therefore suitable for administration to the spinal cord (Yamamoto & Yaksh, 1991) .
The present study investigated the action of the selective NK,-receptor antagonist, RP 67580, in a model of visceral and somatic chemonociception in anaesthetized rats. RP 67580 was chosen because of its higher affinity for the rat NK1-receptor than CP-96,345 (Fong et al., 1992; Fardin et al., 1993b) .
Methods
Experimental setup Sprague-Dawley rats of either sex (200-300 g body weight; Forschungsanstalt fur Versuchstierkunde, Himberg, Austria) ' Author for correspondence.
were fasted overnight with free access to tap water. The experimental setup has been described in detail earlier (Holzer-Petsche, 1992) . In brief, under phenobarbitone anaesthesia (250 mg kg-1, i.p.) the trachea was cannulated and the oesophagus ligated in the neck. Blood pressure was monitored from a carotid artery, a jugular vein was cannulated for continuous i.v. infusion of a glucose-bicarbonate buffer (1.5 ml h') and drug injections. After laparotomy, a cannula was introduced into the stomach via the pylorus for measurement of isometric gastric contractions at a constant volume of 5 ml isotonic saline. A fall in mean arterial blood pressure (MAP) and intragastric pressure (IGP) was taken to indicate nociception (Cervero & McRitchie, 1982; HolzerPetsche, 1992) .
For injection of algesic chemicals, up to five PE-10 cannulae were positioned in the peritoneal cavity between folds of the mesentery, taking care to avoid direct contact of the tips of the i.p. catheters with the stomach. In some experiments similar cannulae were also introduced into the abdominal subcutis. Body temperature was kept constant at 37-38°C by means of a heating pad.
HCI and capsaicin were used as algesic compounds and always injected in a volume of 100jtl. At antagonist. Because the magnitude of the responses did not correlate well with the doses of capsaicin, the results were evaluated as all-or-none effects. For intrathecal injections, a PE-10 cannula was introduced at the beginning of the experiment through the cisterna magna so that its tip lay at the dorsal surface of the spinal cord at the lower thoracic/upper lumbar level. Injection volumes were 10 gl. The correct position of the cannula was verified by injecting 10 ptl Evans blue at the end of the experiment and inspecting the distribution of the dye.
Statistics
Values are presented as means ± s.e.mean. Statistical comparisons were made using the Wilcoxon-Pratt test or Fisher's exact test for 2 x 2 tables, both one-sided, rejecting the null hypothesis if the treatment reduced the reflex response. In the case of testing RP 67580 against the hypotensive effect of substance P the Quade test was used (Conover, 1980) . P<0.05 was regarded as statistically significant.
In control experiments, vehicle (HCl) was administered i.v. at a concentration of 4.6 mmol '-I (1 ml kg-') corresponding to 1 mg kg-' RP 67580 or at a concentration of 11.5 mmol -l (2 ml kg-'), which corresponded to 5 mg kg-' of the antagonist. These injections did not significantly influence the reflex changes of MAP and IGP in response to i.p. or s.c. injection of threshold doses of HCI or capsaicin (Table 1) . As to RP 67580, 5 mg kg-' (11.4 pmol kg-') significantly inhibited only the changes in IGP after i.p. injection of capsaicin while having no statistically significant effect on the other parameters measured (Table 1) . For reasons of solubility, higher doses of RP 67580 could not be tested.
In most control rats (vehicle i.v.), 3 pmol PGE2 injected prior to, and through the same cannula as, capsaicin caused sensitization. This means that changes in MAP and IGP occurred in response to previously subthreshold doses of capsaicin. After RP 67580 (1 mg kg-', i.v.), the proportion of or of equal volumes of vehicle had no effect (Figure 2 ). Amann & Donnerer (1993) .
In assessing the above findings, one has to examine those models of nociception where NK,-antagonists have proven active: non-peptide NK,-antagonists display antinociceptive actions preferably in models of nociception involving inflammatory or sensitizing events. These include thermal hyperalgesia induced by heat (Yashpal et al., 1993) as well as the second phase of pain-related behaviour in the formalin test (Yamamoto & Yaksh, 1991; Berge & Stahlberg, 1993; Yashpal et al., 1993; Chapman & Dickenson, 1993) . This suggests that substance P plays a role in the development of the inflammation or of the hyperalgesia accompanying this inflammation rather than in the transmission of the acute noxious stimulus. Reports on acute antinociceptive actions of NK,-antagonists are equivocal, but the tendency for the substances to block nociceptive reflexes seems to be greater when they are administered directly to the spinal cord rather than in the periphery (Radharkrishnan & Henry, 1991; Chapman & Dickenson, 1993) .
While CP-96,345 has been shown to penetrate the bloodbrain well enough (Lecci et al., 1991) , the present study indicates the opposite for RP 67580, as is also emphasized by Fardin et al. (1993a) . This differs from the conclusion drawn by Laird et al. (1993) from their observation that i.v. administered RP 67580 inhibits the facilitation of a nociceptive spinal flexion reflex in anaesthetized rats. However, their results might also be interpreted as RP 67580 inhibiting facilitation at a peripheral level: the conditioning stimulus to the afferent C-fibres might release enough substance P from the peripheral nerve endings in order to lead to a short-lived sensitization of the afferent fibres.
Several studies indicate a peripheral role of substance P via NKI-receptors in sensitizing afferent nerve endings. Kessler et al. (1992) have demonstrated on a rat skin-nerve preparation in vitro that substance P sensitizes nociceptors to a mixture of inflammatory mediators. Yamamoto et al. (1993) (Prabhakar et al., 1993) . According to these authors this might imply that substance P from glomus cells is involved in exciting afferent nerve endings via NKIreceptors. Thus there is quite some evidence in favour of substance P sensitizing or even exciting peripheral afferent endings. Even the effectiveness of RP 67580 in the writhing test (Garret et al., 1992) might possibly be attributed to a peripheral action: the behaviour in the writhing test usually takes a few minutes to develop. It is conceivable that during this time lag sensitization phenomena are initiated, which might be blunted by peripherally acting NKI-antagonists.
The mechanism of such a sensitization is, however, still far from being elucidated. It is known that substance P releases prostaglandins from a variety of cells, for example, synoviocytes (Lotz et al., 1987) , or spinal cord astrocytes (Marriott et al., 1991) . These prostaglandins, in turn, can sensitize nociceptive nerve endings to subsequent stimuli. However, there are data indicating also the opposite sequence of events, i.e. prostaglandins apparently releasing substance P: Nakamura-Craig & Smith (1989) showed that repeated subplantar injections of substance P or PGE2 caused mechanical hyperalgesia in rats pretreated with indomethacin. A substance P antagonist blocked the sensitization by substance P as well as that by PGE2. In fact, in cultures of chick embryo dorsal root ganglion cells PGE2 was directly observed to release substance P (Nicol et al., 1992) . Such a mechanism might also apply in the present model of sensitization by PGE2.
In conclusion, the results of the present study indicate that central NK1-receptors contribute to the direct transmission of painful chemical stimuli, while peripheral receptors play a role in sensitization phenomena.
